GALNT12

Across TCGA pan-cancer cohorts, GALNT12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GALNT12 data layer compared with 22 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GALNT12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GALNT12 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, LUAD, and HNSC are the cancer types where GALNT12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.574	0.819	<.001	36	view →
LUAD	OS	Median	All	0.761	0.964	.021	8	view →
HNSC	DFS	Median	IV	0.920	1.000	.028	8	view →
PDAC	OS	Quartile	II,III,IV	0.547	0.257	.034	3	view →
UCEC	OS	Quartile	All	1.000	0.829	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GALNT12–LSCC (DFS)

Open the LSCC breakdown →